Disposition of 7482 shares by Simon Harford of Amicus Therapeutics at 9.31 subject to Rule 16b-3

FOLD Stock  USD 9.41  0.05  0.53%   
About 59% of Amicus Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Amicus Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Amicus Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Amicus Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Amicus Therapeutics Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  
Disposition of 7482 common stock at 9.31 of Amicus Therapeutics by Simon Harford on 2nd of January 2025. This event was filed by Amicus Therapeutics with SEC on 2025-01-02. Statement of changes in beneficial ownership - SEC Form 4

Amicus Therapeutics Current Investor Sentiment

Panic Vs Confidence

41

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Amicus Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Amicus Therapeutics.

Amicus Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Amicus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Amicus Therapeutics Historical Investor Sentiment

Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Amicus Therapeutics.

Amicus Therapeutics Fundamental Analysis

We analyze Amicus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amicus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amicus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

Amicus Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Amicus Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Amicus Therapeutics stock to make a market-neutral strategy. Peer analysis of Amicus Therapeutics could also be used in its relative valuation, which is a method of valuing Amicus Therapeutics by comparing valuation metrics with similar companies.

Peers

Amicus Therapeutics Related Equities

LEGNLegend Biotech   6.15   
0%
100.0%
CRNXCrinetics Pharmaceuticals   3.78   
0%
61.0%
HRMYHarmony Biosciences   3.61   
0%
58.0%
RAREUltragenyx   3.20   
0%
52.0%
ARVNArvinas   2.88   
0%
46.0%
AGIOAgios Pharm   2.50   
0%
40.0%
INCYIncyte   2.14   
0%
34.0%
BPMCBlueprint Medicines   1.74   
0%
28.0%
DNLIDenali Therapeutics   1.20   
0%
19.0%
DAWNDay One   1.13   
0%
18.0%
KURAKura Oncology   1.11   
0%
18.0%
ARGXArgenx NV   1.07   
0%
17.0%
BMRNBiomarin Pharmaceutical   0.46   
0%
7.0%
CYTKCytokinetics   0.17   
0%
2.0%
RVMDRevolution Medicines   0.32   
5.0%
0%
INBXInhibrx   0.37   
6.0%
0%
MREOMereo BioPharma   1.38   
22.0%
0%
EWTXEdgewise Therapeutics   1.72   
27.0%
0%
MLYSMineralys Therapeutics,   2.74   
44.0%
0%
DYNDyne Therapeutics   4.33   
70.0%
0%

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Bonds Directory
Find actively traded corporate debentures issued by US companies
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance